Stratos Wealth Advisors LLC Grows Stock Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Stratos Wealth Advisors LLC lifted its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 1.9% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 22,269 shares of the medical equipment provider’s stock after purchasing an additional 406 shares during the period. Stratos Wealth Advisors LLC’s holdings in Lantheus were worth $1,992,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Wilmington Savings Fund Society FSB bought a new position in Lantheus in the third quarter worth approximately $25,000. Signaturefd LLC raised its holdings in Lantheus by 40.5% in the 3rd quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider’s stock worth $35,000 after purchasing an additional 92 shares during the period. UMB Bank n.a. lifted its position in Lantheus by 42.1% during the third quarter. UMB Bank n.a. now owns 425 shares of the medical equipment provider’s stock valued at $47,000 after purchasing an additional 126 shares in the last quarter. GAMMA Investing LLC lifted its position in Lantheus by 45.5% during the third quarter. GAMMA Investing LLC now owns 467 shares of the medical equipment provider’s stock valued at $51,000 after purchasing an additional 146 shares in the last quarter. Finally, Kathleen S. Wright Associates Inc. bought a new stake in Lantheus during the third quarter valued at about $51,000. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Wall Street Analyst Weigh In

LNTH has been the topic of a number of analyst reports. JMP Securities reaffirmed a “market outperform” rating and set a $112.00 price objective on shares of Lantheus in a research report on Tuesday, January 14th. StockNews.com downgraded shares of Lantheus from a “buy” rating to a “hold” rating in a report on Thursday, November 21st. Truist Financial reissued a “buy” rating and issued a $120.00 price objective (down from $135.00) on shares of Lantheus in a research note on Friday, November 8th. Finally, The Goldman Sachs Group began coverage on shares of Lantheus in a research note on Wednesday, December 18th. They set a “buy” rating and a $143.00 target price on the stock. One analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat.com, Lantheus presently has an average rating of “Moderate Buy” and a consensus target price of $131.86.

Lantheus Stock Performance

Shares of NASDAQ:LNTH opened at $90.44 on Thursday. The firm has a market cap of $6.29 billion, a price-to-earnings ratio of 15.05 and a beta of 0.44. The firm has a fifty day moving average price of $92.07 and a 200 day moving average price of $99.10. Lantheus Holdings, Inc. has a fifty-two week low of $53.47 and a fifty-two week high of $126.89.

Insider Buying and Selling at Lantheus

In other news, Director James H. Thrall sold 1,000 shares of Lantheus stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total value of $94,760.00. Following the sale, the director now directly owns 33,207 shares of the company’s stock, valued at approximately $3,146,695.32. The trade was a 2.92 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 2.10% of the company’s stock.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.